Form 13-F position report

SPERO THERAPEUTICS INC

Reported by MORGAN STANLEY

Company profile Manager portfolio Source filing
SPRO CUSIP 84833T103 Manager CIK 0000895421
Latest reported change

Reported 9,221 shares, up 2,250 (32.3%) from the prior quarter.

Reported value 432.8%; share count 32.3% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2025
Shares 9,221 Quarter-end amount reported
Reported value $26,741 Fair value at quarter end
Consecutive quarters held 31 Through Q2 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q2 2026 Reduced 914 -3,638 (-79.9%) < 0.01% $2,020 2026-08-13
Q1 2026 Added 4,552 +4,239 (1354.3%) < 0.01% $10,651 2026-05-15
Q4 2025 Reduced 313 -43,065 (-99.3%) < 0.01% $729 2026-02-13
Q3 2025 Added 43,378 +34,157 (370.4%) < 0.01% $81,550 2025-11-14
Q2 2025 Added 9,221 +2,250 (32.3%) < 0.01% $26,741 2025-08-15
Q1 2025 Unchanged 6,971 0 (0.0%) < 0.01% $5,019 2025-05-15
Q4 2024 Unchanged 6,971 0 (0.0%) < 0.01% $7,180 2025-02-14
Q3 2024 Unchanged 6,971 0 (0.0%) < 0.01% $9,341 2024-11-14
Q2 2024 Reduced 6,971 -928 (-11.7%) < 0.01% $9,062 2024-08-14
Q1 2024 Reduced 7,899 -4,136 (-34.4%) < 0.01% $13,586 2024-05-15
Q4 2023 Added 12,035 +3,047 (33.9%) < 0.01% $17,691 2024-02-13
Q3 2023 Reduced 8,988 -542 (-5.7%) < 0.01% $10,875 2023-11-15
Q2 2023 Reduced 9,530 -5,700 (-37.4%) < 0.01% $13,819 2023-08-14
Q1 2023 Reduced 15,230 -1,847 (-10.8%) < 0.01% $22,084 2023-05-15
Q4 2022 Reduced 17,077 -2,177 (-11.3%) < 0.01% $29,543 2023-02-14
Q3 2022 Reduced 19,254 -174,355 (-90.1%) < 0.01% $38,000 2022-11-14
Q2 2022 Added 193,609 +120,613 (165.2%) < 0.01% $143,000 2022-08-15
Q1 2022 Added 72,996 +22,584 (44.8%) < 0.01% $635,000 2022-05-13
Q4 2021 Reduced 50,412 -6,089 (-10.8%) < 0.01% $807,000 2022-02-14
Q3 2021 Reduced 56,501 -13,271 (-19.0%) < 0.01% $1,041,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history
Institutional context

Who else reported the position

55 managers reported SPERO THERAPEUTICS INC for Q2 2025.

Manager Activity Shares Change % of reported 13F Reported value Tenure
PFIZER INC Unchanged 2,362,348 0 1.19% $6,850,809 3 qtrs
VANGUARD GROUP INC Added 1,950,381 +186,761 < 0.01% $5,656,105 31 qtrs
Anson Funds Management LP Reduced 1,615,469 -2,183,463 0.67% $4,684,860 12 qtrs
Alphabet Inc Unchanged 889,979 0 0.12% $2,580,939 31 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 832,165 -138,742 < 0.01% $2,413,279 14 qtrs
Schonfeld Strategic Advisors LLC New 510,834 +510,834 0.01% $1,481,417 1 qtr
GEODE CAPITAL MANAGEMENT LLC Reduced 510,699 -14,170 < 0.01% $1,481,359 30 qtrs
BlackRock Inc Reduced 434,768 -47,314 < 0.01% $1,260,827 4 qtrs
MONIMUS CAPITAL MANAGEMENT LP Unchanged 310,908 0 0.66% $901,633 3 qtrs
EAM Investors LLC New 239,140 +239,140 0.11% $693,506 1 qtr
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2025
Filed
August 15, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
8,921
Shared
0
None
300

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.